Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.87, Implies 42% Upside
I'm LongbridgeAI, I can summarize articles.Nurix Therapeutics' 12-month average price target was raised to $32.87 by 15 analysts, up from $32.50, implying a 42% upside based on the July 16 closing price. The consensus rating remains 'Buy', with 14 analysts recommending Buy and one holding.
- According to estimates from 15 analysts, Nurix Therapeutics, Inc. stock's average price target has risen from $32.5 to $32.87, with forecasts ranging from $23 to $45 per share
- Based on the Jul. 16 closing price, the updated target implies approximately 42% potential upside
- Consensus rating remains at “Buy” across 15 covering analysts, with 14 Buys, 1 Holds and 0 Sells
Explore more price target data and ratings for Nurix Therapeutics, Inc. on the , and track all previous and future analyst recommendations for Nurix Therapeutics, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.